Mathis Stéphanie, Chapuis Nicolas, Borgeot Jessica, Maynadié Marc, Fontenay Michaela, Béné Marie-Christine, Guy Julien, Bardet Valérie
Service d'Hématologie Biologique, Hôpitaux Universitaires Paris Centre Cochin, Paris, France; Inserm U1016, Université Paris Descartes, Hôpitaux Universitaires Paris Centre Cochin, Paris, France.
Cytometry B Clin Cytom. 2015 Mar;88(2):101-9. doi: 10.1002/cyto.b.21200. Epub 2014 Nov 17.
A seven-color/eight-antibody approach has recently been proposed for the minimal residual disease (MRD) determination in multiple myeloma (MM), which was developed on FACSCantoII instruments. This strategy should be also applicable on different multiparameter flow cytometers (MFC), but this needs to be demonstrated before moving MRD assessment to local flow cytometry core facilities, nearer to patients, thereby reducing the risk of cell losses induced by sample transportation and delays in cell processing.
To evaluate the comparability of testing the same seven-color/eight-antibody single-tube on any instruments, MRD was evaluated concomitantly on two distinct MFC in a cohort of 80 bone marrow MM samples (i.e., 73 patients including seven with two MRD evaluations) in two French centers, Paris-Cochin and Dijon.
No significant difference in the MM residual plasma-cells (MM-PCs) quantification was observed. Calculated on the basis of the whole amount of leukocytes assessed, the mean MRD percentage was, respectively, 0.1661% and 0.1458% using FACSCantoII or Navios instruments, with a very high correlation between instruments (r(2) = 0.9798) and a very minimal bias (-0.02). Moreover, there was no difference in MRD interpretation at 10(-4) threshold; whereas three MRD interpretation discordances were observed at 2.5 × 10(-5) threshold.
This study demonstrates that this MRD-detection strategy is transposable between harmonized ≥ seven-color instruments. This shows that a homogeneous rapid MRD evaluation can be performed in most MFC platforms, in the near vicinity of clinical wards. However, the clinical validation of this approach needs to be strengthened, as well as its relevance compared to molecular approaches.
最近提出了一种用于多发性骨髓瘤（MM）微小残留病（MRD）检测的七色/八抗体方法，该方法是在FACSCantoII仪器上开发的。该策略也应适用于不同的多参数流式细胞仪（MFC），但在将MRD评估转移到更靠近患者的当地流式细胞术核心设施之前，需要对此进行验证，从而降低样本运输和细胞处理延迟导致的细胞损失风险。
为了评估在任何仪器上检测相同的七色/八抗体单管的可比性，在法国的两个中心，即巴黎-科钦中心和第戎中心，对80例骨髓MM样本（即73例患者，其中7例进行了两次MRD评估）的队列同时在两台不同的MFC上进行MRD评估。
在MM残留浆细胞（MM-PCs）定量方面未观察到显著差异。根据评估的白细胞总量计算，使用FACSCantoII或Navios仪器时，平均MRD百分比分别为0.1661%和0.1458%，仪器之间具有非常高的相关性（r(2) = 0.9798）且偏差非常小（-0.02）。此外，在10(-4)阈值时MRD解释没有差异；而在2.5×10(-5)阈值时观察到3例MRD解释不一致。
本研究表明，这种MRD检测策略可在协调一致的≥七色仪器之间转换。这表明在大多数MFC平台上，在临床病房附近可以进行同质快速的MRD评估。然而，这种方法的临床验证需要加强，以及与分子方法相比的相关性也需要加强。
